Burningham Z, Hashibe M, Spector L et al (2012) The epidemiology of sarcoma. Clin Sarcoma Res 2(1):14

Article  PubMed  PubMed Central  Google Scholar 

Weiss AR, Harrison DJ (2024) Soft tissue sarcomas in adolescents and young adults. J Clin Oncol 42(6):675–685

Article  CAS  PubMed  Google Scholar 

Spira AI, Ettinger DS (2002) The use of chemotherapy in soft-tissue sarcomas. Oncologist 7(4):348–359

Article  CAS  PubMed  Google Scholar 

Kasper B (2019) The challenge of finding new therapeutic avenues in soft tissue sarcomas. Clin Sarcoma Res 9:5

Article  PubMed  PubMed Central  Google Scholar 

Fernández-Ortega P, Caloto MT, Chirveches E et al (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer 20(12):3141–3148

Article  PubMed  Google Scholar 

Grunberg SM (2009) Obstacles to the implementation of antiemetic guidelines. J Natl Compr Canc Netw 7(5):601–605

Article  PubMed  Google Scholar 

Tanaka K, Mizusawa J, Fukuda H et al (2015) Perioperative chemotherapy with ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities (JCOG0304). Jpn J Clin Oncol 45(6):555–561

PubMed  Google Scholar 

Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO Guideline Update. J Clin Oncol 38(24):2782–2797

Article  CAS  PubMed  Google Scholar 

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis Version 1. 2024. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf Accessed 1 July 2024.

Jordan K, Chan A, Gralla RJ et al (2023) Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC/ESMO consensus recommendation. Support Care Cancer 32(1):53

Article  PubMed  PubMed Central  Google Scholar 

Iihara H, Abe M, Wada M et al (2024) 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol 29(7):873–888

Article  PubMed  PubMed Central  Google Scholar 

Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655–1663

Article  PubMed  Google Scholar 

Rapoport BL, Herrstedt J, Snow RC et al (2023) 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 32(1):36

Article  PubMed  PubMed Central  Google Scholar 

Kusaba H, Kumagai H, Inadomi K et al (2016) Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy. Medicine (Baltimore) 95(49):e5460

Article  CAS  PubMed  Google Scholar 

Iihara H, Fujii H, Yoshimi C et al (2016) Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol 21(2):409–418

Article  CAS  PubMed  Google Scholar 

Iihara H, Ishihara M, Fujii H et al (2016) Comparison of the control of nausea and vomiting among several moderately emetic-risk chemotherapy regimens. J Cancer 18;7(5):569–75

Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21(1):1–12

Article  PubMed  Google Scholar 

U.S. Department of Health and Human Services, National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. Available online: https://www.eortc.be/services/doc/ctc/ Accessed 19 Sep 2022.

Warr D (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192–196

Article  CAS  PubMed  Google Scholar 

Tanaka K, Ozaki T (2021) Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol 51(2):180–184

Article  PubMed  Google Scholar 

Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134–142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizukami N, Yamauchi M, Koike K et al (2014) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 47(3):542–550

Article  PubMed  Google Scholar 

Abe M, Hirashima Y, Kasamatsu Y et al (2016) Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 24(2):675–682

Article  PubMed  Google Scholar 

Nakashima K, Murakami H, Yokoyama K et al (2017) A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy. Jpn J Clin Oncol 47(9):840–843

Article  PubMed  Google Scholar 

Yanai T, Iwasa S, Hashimoto H et al (2018) A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 23(2):382–388

Article  CAS  PubMed  Google Scholar 

Sandhya L, Devi Sreenivasan N, Goenka L et al (2023) Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol 41(14):2617–2627

Article  CAS  PubMed  Google Scholar 

Hori Y, Sakamoto A, Goto T et al (2018) Analysis of dietary intake during consecutive-day chemotherapy for bone and soft-tissue sarcomas. Front Nutr 4:70

Article  PubMed  PubMed Central  Google Scholar 

Shahrami B, Biglari M, Kaveh-Ahangaran R et al (2023) (2023) Pharmacotherapy considerations in antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. Eur J Cancer Care (Engl) 1:6650915

Google Scholar 

Patel P, Leeder JS, Piquette-Miller M et al (2017) Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 83(10):2148–2162

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kataria PS, Kendre PP, Patel AA (2017) Ifosfamide-induced encephalopathy precipitated by aprepitant: a rarely manifested side effect of drug interaction. J Pharmacol Pharmacother 8(1):38–40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bun S, Yonemori K, Akagi T et al (2018) Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. Invest New Drugs 36(1):151–155

Article  CAS  PubMed  Google Scholar